Location aims to translate research into multiple real-world treatments.
With the goal of translating breakthroughs in cell therapy research into real-world treatments for people with diseases such as chronic heart failure, Parkinson’s, kidney disease, type 1 diabetes, and several forms of cancer, the Novo Nordisk Foundation has officially dedicated approximately $135 million to a new cell therapy facility. Located at the Technical University of Denmark (DTU) in Lyngby, the center will serve public, private, national, and international clients from academia, biotech, and the pharmaceutical industry. It is expected to be ready in 2027.
“Cell therapies have the potential to take us from treating or managing the symptoms of chronic diseases to treating the disease itself, or even curing it with a one-off procedure,” says Thomas H.R. Carlsen, CEO, the Novo Nordisk Foundation Cellerator. “We’ve seen major advances in the laboratory in recent years, but many promising cell therapy candidates face difficulties reaching clinical trials, partly because we can’t currently develop cell therapy products in large, consistent quantities here in Denmark. I’m thrilled to be heading an initiative that will change this and provide hope to people living with chronic diseases.”
Reference: New cell therapy facility enters fight against chronic diseases. Novo Nordisk Fonden. September 21, 2023. Accessed September 22, 2023. https://novonordiskfonden.dk/en/news/new-cell-therapy-facility-enters-fight-against-chronic-diseases/
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.